Asceniv

Asceniv is a human immune globulin product used for the treatment of primary humoral immunodeficiency (PI). It is an intravenous immunoglobulin (IVIG) therapy that provides patients with antibodies needed to fight infections. Asceniv is manufactured by ADMA Biologics, a biopharmaceutical company specializing in the development and commercialization of plasma-derived therapeutics.

Composition and Production

Asceniv is derived from human plasma and contains a broad spectrum of antibodies. The plasma used in the production of Asceniv is collected from healthy donors and undergoes rigorous screening and testing to ensure safety and efficacy. The manufacturing process includes steps to inactivate and remove potential pathogens, ensuring the final product is safe for patient use.

Indications

Asceniv is indicated for the treatment of primary humoral immunodeficiency (PI), which includes a group of disorders characterized by an inability to produce adequate amounts of antibodies. These disorders include, but are not limited to:

• Common Variable Immunodeficiency (CVID)
• X-linked Agammaglobulinemia (XLA)
• Severe Combined Immunodeficiency (SCID)
• Wiskott-Aldrich Syndrome (WAS)

Administration

Asceniv is administered intravenously, typically in a healthcare setting under the supervision of a healthcare professional. The dosage and frequency of administration depend on the patient's weight, clinical condition, and response to therapy. It is important to monitor patients for any adverse reactions during and after the infusion.

Mechanism of Action

Asceniv works by providing exogenous antibodies that help to enhance the immune response in patients with primary humoral immunodeficiency. These antibodies can neutralize pathogens, opsonize bacteria for phagocytosis, and modulate the immune system to improve the patient's ability to fight infections.

Side Effects

Common side effects of Asceniv may include:

• Headache
• Fever
• Nausea
• Fatigue
• Chills
• Muscle pain

Serious side effects, although rare, can occur and may include:

• Anaphylactic reactions
• Thrombotic events
• Renal dysfunction or failure
• Hemolysis

Patients should be monitored for any signs of adverse reactions, and appropriate medical intervention should be provided if necessary.

Related Pages

• ADMA Biologics
• Intravenous Immunoglobulin
• Primary Immunodeficiency
• Common Variable Immunodeficiency
• X-linked Agammaglobulinemia
• Severe Combined Immunodeficiency
• Wiskott-Aldrich Syndrome